- Home
- RPTX vs VANI Comparison
RPTX vs VANI Comparison
Compare RPTX & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- VANI
- Stock Information
- Founded
- RPTX 2016
- VANI 1998
- Country
- RPTX Canada
- VANI United States
- Employees
- RPTX N/A
- VANI N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RPTX Health Care
- VANI Health Care
- Exchange
- RPTX Nasdaq
- VANI Nasdaq
- Market Cap
- RPTX 78.2M
- VANI 81.2M
- IPO Year
- RPTX 2020
- VANI 2014
- Fundamental
- Price
- RPTX $1.95
- VANI $1.60
- Analyst Decision
- RPTX Strong Buy
- VANI Strong Buy
- Analyst Count
- RPTX 3
- VANI 1
- Target Price
- RPTX $4.50
- VANI $4.00
- AVG Volume (30 Days)
- RPTX 192.1K
- VANI 257.3K
- Earning Date
- RPTX 11-07-2025
- VANI 11-12-2025
- Dividend Yield
- RPTX N/A
- VANI N/A
- EPS Growth
- RPTX N/A
- VANI N/A
- EPS
- RPTX N/A
- VANI N/A
- Revenue
- RPTX $250,000.00
- VANI N/A
- Revenue This Year
- RPTX N/A
- VANI N/A
- Revenue Next Year
- RPTX N/A
- VANI N/A
- P/E Ratio
- RPTX N/A
- VANI N/A
- Revenue Growth
- RPTX N/A
- VANI N/A
- 52 Week Low
- RPTX $0.89
- VANI $0.91
- 52 Week High
- RPTX $4.07
- VANI $1.92
- Technical
- Relative Strength Index (RSI)
- RPTX 68.62
- VANI 57.05
- Support Level
- RPTX $1.74
- VANI $1.57
- Resistance Level
- RPTX $1.97
- VANI $1.92
- Average True Range (ATR)
- RPTX 0.08
- VANI 0.12
- MACD
- RPTX 0.01
- VANI 0.02
- Stochastic Oscillator
- RPTX 91.49
- VANI 48.36
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.